Evidence map›Paper›PMID 33823783›Full record

ArticleBMC infectious diseases2021

Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis.

Patrizia Künzler-Heule, Katharina Fierz, Axel Jeremias Schmidt, Manuela Rasi, Jasmina Bogdanovic, Agnes Kocher, Sandra Engberg, Manuel Battegay, Christiana Nöstlinger, Andreas Lehner and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02785666 (A Phase III, Multi-center, Open-label Trial to Investigate the Impact of a Treat, Counsel and Cure Strategy in Men Who Have Sex With Men With Hepatitis C Infection in the Swiss HIV Cohort Study), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02785666 phase3completednot on this map

A Phase III, Multi-center, Open-label Trial to Investigate the Impact of a Treat, Counsel and Cure Strategy in Men Who Have Sex With Men With Hepatitis C Infection in the Swiss HIV Cohort Study

TypeinterventionalSponsorUniversity of ZurichRan2016 to 2018Enrolled150ConditionsHepatitis C, HIVArmsgrazoprevir/elbasvir, ribavirin, Behavioural Intervention
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Patrizia Künzler-HeuleNursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland.
Katharina FierzZurich University of Applied Sciences (ZUAS), Winterthur, Switzerland.
Axel Jeremias SchmidtDivision of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Manuela RasiDepartment of Public & Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Jasmina BogdanovicNursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland.
Agnes KocherNursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland.
Sandra EngbergNursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland.
Manuel BattegayDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Christiana NöstlingerInstitute of Tropical Medicine, Department of Public Health, Antwerp, Belgium.
Andreas LehnerAIDS-Hilfe Schweiz, Zurich, Switzerland.
Roger KouyosDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Patrick SchmidDivision of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Dominique Laurent BraunDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Jan FehrDepartment of Public & Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Dunja NiccaNursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland. dunja.nicca@unibas.ch.
University of Basel · CHUniversity of Zurich · CHKantonsspital St. Gallen · CHInstituut voor Tropische Geneeskunde · BESwiss AIDS Federation · CHUniversity Hospital of Zurich · CHUniversity of Pittsburgh · USZHAW Zurich University of Applied Sciences · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis C virus reinfections in HIV-positive men-who-have-sex-with-men (MSM) challenge the effectiveness of antiviral treatment. To fight this problem, an adapted sexual risk reduction intervention was implemented within a hepatitis C treatment trial. Following this, the current study had two aims and describes 1) how the program was received by participants; and 2) their responses to the program regarding sexual risk taking. Based on the participants' input, we hoped to judge the intervention's potential for scale-up.

methodsSeventeen participants who received the sexual risk reduction intervention in addition to hepatitis C treatment were recruited for semi-structured interviews six to 12 months post-intervention. We evaluated the responses via reflexive thematic analysis and applied the concept of sense-making.

resultsGiving hepatitis C a place and living without it again illustrates how participants received the program and how their experiences were altered by the impact of sense-making. Based on their responses, we allocated participants to three groups: 1. Avoid risks: get rid of hepatitis C for life. For these men, hepatitis C remained a life-threatening disease: they actively modified their risk behavior and felt supported by the intervention in maintaining their behavioral changes. 2. Minimize risks: live as long as possible without hepatitis C. In contrast to group 1, these men saw hepatitis C as a manageable disease. The intervention facilitated reflection on risks and how to develop behavioral changes that suited them individually. 3. Accept risks; live with the risk of hepatitis C. These men perceived behavioral changes as much more difficult than "easy" medical treatment. They expected to either undergo repeated rounds of treatment or stay HCV re-infected.

conclusionThese results illustrate the diversity of men's responses and their decisions regarding sexual risk behavior after participating in a combination of antiviral treatment and a sexual risk reduction intervention. Two major aspects were identified: 1) Teachable moments, particularly at the time of diagnosis/treatment, could offer an opportunity to develop openness for behavioral change; 2) adapting sexual risk reduction interventions to sense-making patterns could help to improve its effectiveness. Support for reducing infection risk and raising awareness of preventative measures are additional benefits.

trial registrationClinical Trial Number: NCT02785666 , 30.05.2016.

Indexed as

AdultAntiviral AgentsCoinfectionHepatitis CHIV InfectionsHomosexuality, MaleHumansInterviews as TopicMaleMiddle AgedProgram EvaluationRisk Reduction BehaviorAntiviral AgentsHealth behaviorHepatitis CHIVMSMQualitativeSense-making

Identifiers

PMID33823783
PMCPMC8022541
OpenAlexW3147877214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.